Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Increases By 47.9%

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 853,600 shares, an increase of 47.9% from the December 15th total of 577,200 shares. Based on an average daily volume of 162,900 shares, the short-interest ratio is presently 5.2 days. Approximately 1.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $38.67.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several hedge funds have recently modified their holdings of the company. GAMMA Investing LLC bought a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $29,000. BNP Paribas Financial Markets grew its position in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after buying an additional 5,900 shares during the last quarter. Walleye Capital LLC grew its position in shares of ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after buying an additional 80,807 shares during the last quarter. abrdn plc grew its position in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after buying an additional 198,225 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

ABIVAX Société Anonyme Trading Up 2.3 %

Shares of NASDAQ ABVX traded up $0.14 during mid-day trading on Wednesday, hitting $6.29. 162,353 shares of the stock traded hands, compared to its average volume of 161,273. ABIVAX Société Anonyme has a twelve month low of $5.54 and a twelve month high of $17.02. The firm has a 50 day simple moving average of $8.22 and a two-hundred day simple moving average of $10.33.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.